Nykode Therapeutics reports full year 2021 financial results

On March 31, 2022 Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, reported that the Board of Directors has approved the Company’s financial statements for 2021 (Press release, Nykode Therapeutics, MAR 31, 2022, View Source [SID1234611277]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2021 was another year of significant progress for Nykode," said Michael Engsig, Chief Executive Officer of Nykode Therapeutics. "We launched our new company name and brand identity, a first step in our journey to become a leading global immunotherapy company. We signed two transformative research licensing agreements with Adaptive Biotechnologies and Regeneron, which will accelerate the development of our technology platform across multiple areas of high unmet need. In addition, we made substantial progress in the development of our oncology and infectious disease pipelines, including dosing the first subjects in our Phase I/II clinical trial of Nykode’s next-generation SARSCoV-2 vaccine candidates. Furthermore, we expanded and evolved the organization to over 100 employees, adding new valuable skills and capabilities to our team. We believe Nykode is wellpositioned to continue to execute on our world-class collaborations and advance our technology platform and clinical programs, and we look forward to sharing updates this year."

Highlights for 2021
• March-Adopted IFRS (International Financial Reporting Standards) and announced initiative to explore a potential listing of its shares on the Nasdaq Global Market in the US
• March – Nykode’s first IND was opened in the VB10.NEO program
• June-Initiated a Phase I/II trial to evaluate two next-generation SARS-CoV-2 virus DNA vaccine candidates to address emerging variants of concern
• July-Entered into worldwide in-licensing agreement with Adaptive Biotechnologies for clinically validated SARS-CoV-2 T cell epitopes to combine in next-generation T cell vaccine candidate to specifically address emerging SARS-CoV-2 variants of concern
• November-First subject dosed in Phase I/II clinical trial with next-generation SARS-CoV-2 vaccine candidates
• November-Nykode announced a change of company name from Vaccibody to Nykode Therapeutics
• November-Entered into multi-target license and collaboration agreement with Regeneron
• December-Announced first subject dosed with its T cell-focused next-generation SARSCoV-2 vaccine candidate

Full year 2021 key figures
• Total operating income of USD 35.8 million in 2021, compared to USD 215.7 million in 2020
• Total operating expenses of USD 46.5 million in 2021, compared to USD 37.4 million in 2020
• Net loss of USD 9.4 million in 2021, compared to a net profit of USD 149.8 million in 2020
• Cash and cash equivalents of USD 216.2 million at year-end 2021, compared to USD 183.9 million at year-end 2020 • Other current financial assets of USD 12.2 million at year-end 2021, compared to USD 24.9 million at year-end 2020 • Total equity of USD 194.1 million at year-end 2021, compared to USD 178.9 million at yearend 2020
• Total assets of USD 265.6 million at year-end 2021, compared to USD 230.0 million at yearend 2020

—The Company’s annual accounts for the financial year 2021, including the financial statements and annual report, are together with the auditor’s report attached to this announcement. Investors and analysts are invited to join a webcast presentation of the 2021 financial results conducted by CEO Michael Engsig and other members of management April 1, 2022, at 11.30 a.m. CET / 5.30 a.m. ET.

An updated corporate presentation will be available in the Investors section of the Company’s website at 7:00 a.m. CET on April 1 at www.nykode.com/investors. The live and archived webcast of the presentation can be accessed in the Investors section of the Company’s website here.

Nirogy Therapeutics Presented at Keystone Symposia on Cancer Immunotherapy: Decoding the cancer immunity interactome. British Columbia, CANADA

On March 31, 2022 Nirogy Therapeutics, a biopharmaceutical company focused on oncology and Immune diseases, reported that presented at the Cancer Immunotherapy: Decoding the cancer immunity interactome, Keystone Conference that took place from March 21-25, 2022 (Press release, Nirogy Therapeutics, MAR 31, 2022, View Source [SID1234611276]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A poster highlighting pre-clinical data of a small molecule dual inhibitor of lactate transporters demonstrates the potential of immune activation in the TME by differential metabolic reprogramming of various immune cells in the TME on treatment with the compound.

nirogy therapeutics to- present at keystone symposia on cancer immunotherapy decoding the cancer immunity interactome british columbia canada
The conference poster presentation "A dual MCT1 and MCT4 inhibitor blocking lactate transport impacts human immune cell response under conditions mimicking the tumor microenvironment" is available on our website at View Source

Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022

On March 31, 2022 Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), reported that it will present new preclinical data confirming AsiDNA’s abilities to protect from anticancer treatment toxicity and fight tumor resistance during poster and oral sessions at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (AACR Annual Meeting 2022, April 8-13, 2022) (Press release, Onxeo, MAR 31, 2022, View Source [SID1234611270]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will describe how AsiDNA efficiently prevented the emergence of resistances to tyrosine kinase inhibitors in several models of targetable oncogenic addiction and will point to the therapeutic opportunity of combining AsiDNA and TKI (tyrosine kinase inhibitors) to overcome resistance in a clinical setting. These data were obtained within the framework of the collaboration with Pr. Gilles Favre (Cancer Research Center of Toulouse).

The poster presentation supports AsiDNA’s potential to protect healthy cells from toxicities of several anti-cancer treatments. When combined with different anti-cancer treatments (Carboplatin+/-Paclitaxel in long-term treatment, Radiotherapy, Doxorubicin, PARP inhibitors), AsiDNA induces its nuclear target engagement only in dividing cells, while preserving healthy non dividing cells. In addition, in certain proliferating healthy cells, AsiDNA induces a stop in their division or boosts their DNA repair activity, thus protecting them from the toxic effects of anti-cancer treatments. These data were obtained in in vivo and in vitro models within the framework of the collaboration with Pr. Marie Dutreix (Institut Curie).

Wael Jdey, Preclinical Lead of Onxeo, stated: "These new data accepted for presentation at the AACR (Free AACR Whitepaper) 2022 complement the pre-clinical and clinical package already obtained with AsiDNA. With its differentiated mechanism of action, AsiDNA has shown its ability to work in the new preclinical tumor models that are resistant to TKi’s especially Osimertinib in EGFR-mutated NSCLC models. We are excited to present these data to the scientific community and are looking forward to initiating the next steps of the AsiDNA development plan".

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

On March 31, 2022 Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) reported the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study following an independent review by the study’s Data Safety Monitoring Board (DSMB) (Press release, Oncolytics Biotech, MAR 31, 2022, View Source [SID1234611269]). The DSMB noted no safety concerns in these patients and has recommended that the study proceed to full enrollment pending clearance by the Paul Ehrlich Institute (PEI; Germany’s medical regulatory body). The PEI recently cleared the study’s pancreatic cancer cohort for full enrollment following a similar recommendation by the DSMB. The trial’s anal cancer and first-line mCRC cohorts do not include safety run-ins and are proceeding as planned.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The GOBLET study is designed to evaluate the safety and efficacy of pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab in patients with metastatic pancreatic, metastatic colorectal, and advanced anal cancers. The study includes 14 clinical trial sites across Germany and is being managed by AIO, a leading academic cooperative medical oncology group.

"The successful completion of GOBLET’s final safety run-in underscores the trial’s strong momentum and supports the ability of pelareorep to be safely combined with checkpoint inhibitors," said Thomas Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics. "This achievement positions us to continue building on prior clinical data that demonstrate the potential of pelareorep to provide a clinical benefit in colorectal and other gastrointestinal (GI) cancers. Existing data suggest this clinical benefit likely results from the stimulation of protective immune responses that may be enhanced by the addition of checkpoint inhibition. Given the high prevalence of GI malignancies, including colorectal and pancreatic cancer, and the fact that most cases do not respond to checkpoint inhibition, we view GOBLET as an important opportunity to evaluate a novel therapeutic approach that may address a pressing unmet medical need."

The GOBLET study’s metastatic colorectal cancer cohorts are supported by prior clinical data demonstrating adaptive anti-tumor immune responses and a 90% clinical benefit rate in KRAS-mutated mCRC patients treated with a pelareorep-based combination (link to PR, link to study). In addition to primary endpoints evaluating safety and efficacy, GOBLET also includes exploratory endpoints designed to explore the potential of CEACAM6 and T cell clonality to serve as predictive biomarkers. This may increase the likelihood of success of future registrational studies by allowing for the selection of the most appropriate patients.

About GOBLET
The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication study in advanced or metastatic gastrointestinal tumors. The study is being conducted at 14 centers in Germany. The co-primary endpoints of the study are objective response rate (ORR) assessed at week 16 and safety. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers (T cell clonality and CEACAM6). The study employs a Simon two-stage design with Stage 1 comprising four treatment groups expected to enroll a total of approximately 55 patients:
1.Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients (n=12);
2.Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients (n=19);

3.Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients (n=14); and
4.Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients (n=10).

Any cohort showing an ORR above a pre-specified threshold in Stage 1 may be advanced to Stage 2 and enroll additional patients.

About AIO
AIO-Studien-gGmbH (AIO) emerged from the study center of the internal oncology working group within the German Cancer Society (DKG). AIO operates with a non-profit purpose of promoting science and research with a focus on internal oncology. Since its foundation, AIO has become a successful sponsor and study management company and has established itself both nationally and internationally.

About Gastrointestinal Cancer
Excluding skin cancers, colorectal cancer is the third most common cancer, with estimates indicating that 106,180 new cases of colon cancer and 44,850 new cases of rectal cancer will be diagnosed in the U.S. in 20221. Also, for the 2022 year, the American Cancer Society estimates there will be 62,210 new cases of pancreatic cancer2 and 9,440 new cases of anal cancer3 in the U.S.

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

On March 31, 2022 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported financial results for the year ended December 31, 2021 and provided a corporate update on key events since the start of 2021 (Press release, Vaccinex, MAR 31, 2022, View Source [SID1234611268]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"I am pleased to report that the last 15 months have been extremely productive for Vaccinex. We are advancing the development of pepinemab for oncology and neurodegenerative disease and have made good progress in each of the clinical programs in these diseases. These programs build on a comprehensive body of prior preclinical and clinical studies that provide a strong foundation of understanding of the mechanism of action of this novel immunomodulator," said Maurice Zauderer, Ph.D., President and Chief Executive Officer of Vaccinex.

Dr. Zauderer continued, "In the open label, Phase 1b/2 KEYNOTE-B84 trial of pepinemab in combination with KEYTRUDA (pembrolizumab) as first-line treatment for recurrent or metastatic head and neck cancer, we observed two complete responses (CRs) in the first three patients enrolled. We will review details of those responses and promising Phase 1b safety results that opened enrollment into the Phase 2 expansion of this study at the American Society for Cancer Research (AACR 2022) on Monday, April 11, 2022."

"In addition, phase 1 has been completed and enrollment is underway in Phase 2a expansion of the SIGNAL-AD trial in early Alzheimer’s Disease. Looking ahead to 2022 and early 2023, we expect to complete enrollment in the KEYNOTE-B84 and SIGNAL-AD trials. Data from these studies will help to guide the regulatory and product development path for the pepinemab programs. We look forward to continue to update the clinical community and investors on our progress at other medical conferences in 2022."

Pepinemab Clinical Updates:

Oncology: Head and Neck Cancer

Enrollment is underway in the Phase 1b/2 clinical trial evaluating pepinemab in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) for first-line treatment in recurrent or metastatic head and neck cancer.

Multiple prior studies suggest that inhibition of SEMA4D increases immune infiltration and alters the balance of cytotoxic and immunosuppressive cells in the tumor microenvironment. As SEMA4D is highly expressed and has been shown to promotes immunosuppression in head and neck cancer, there is strong rationale for development in this indication.

In January 2022, Vaccinex reported that, based on data from the phase 1b segment, the Data Safety Monitoring Board approved the recommended phase 2 dose and initiation of enrollment into the Phase 2 expansion segment of the trial. Importantly, two complete responses were observed among the three patients enrolled in phase 1b.

Vaccinex expects to report further data from this study (Abstract CT-111) at the AACR (Free AACR Whitepaper) 2022 on Monday, April 11, 2022 in the Phase II Clinical Trials session.

The KEYNOTE-B84 study is expected to enroll up to 65 subjects across 18 U.S. trial sites and will assess whether immunotherapy with pepinemab in combination with pembrolizumab can improve responses in the front-line setting. The primary outcome of the study is objective response, and additional outcomes include progression free survival and overall survival.

Vaccinex anticipates that study enrollment will conclude in 2023. The Company expects to continue to provide additional updates from this open label trial at medical conferences in 2022 and results for the primary outcome in 2023.

Other Oncology Trials. Pepinemab is also being evaluated in multiple investigator-sponsored trials (ISTs) in pancreatic and breast cancer and in "window of opportunity" studies, including head and neck cancer and melanoma to evaluate pepinemab in several combination treatments.

Neurodegenerative Disease:

Alzheimer’s Disease. Enrollment continues in the Phase 1/2a SIGNAL-AD trial of pepinemab as a single agent in early Alzheimer’s disease. This trial is being funded in part by the Alzheimer’s Drug Discovery Foundation and by the Alzheimer’s Association under the 2020 Part the Cloud Program.

The randomized, double-blind, placebo-controlled, multi-center safety and biomarker study of pepinemab in early AD is planned to enroll 40 subjects across 15 U.S. trial sites. Vaccinex anticipates topline data from this study in 2023.

Huntington’s disease. The Phase 2 double-blind, placebo-controlled SIGNAL trial of pepinemab in patients with early Huntington’s disease (HD) has been completed, and Vaccinex believes the program is Phase-3 ready.

While the Phase 2 study did not meet the prespecified primary endpoints, we believe that multiple exploratory and post-hoc analyses support the potential cognitive benefit of treatment with pepinemab in early manifest HD patients, particularly those with evidence of mild cognitive or functional deficits at baseline including:

Highly significant improvement (p=0.007) in the Huntington’s Disease Cognitive Assessment Battery (HD-CAB) Composite score, a measure comprised of 6 different cognitive assessments that has also been employed in other HD trials.
Significant benefit in reducing apathy severity (p=0.017, 1-sided), a problem behavior that has previously been correlated with cognition in both HD and AD.
Reduced atrophy (p=0.017) in caudate region of striatum, a brain region known to degenerate early in HD progression, along with a striking increase in brain metabolic activity as measured by FDG-PET in most brain regions. Decline in FDG-PET signal has been reported to correlate with cognitive decline and clinical progression in several studies of AD.
The Company continues to actively explore advancing pepinemab into a Phase 3 HD trial in collaboration with biopharmaceutical partners.

Upcoming Anticipated Milestones:

Oncology:

Phase 1b/2 Keynote B84 Trial: Open label head and neck cancer trial of pepinemab in combination with KEYTRUDA/pembrolizumab. Multiple interim data read-outs expected in 2022. Enrollment is expected to be completed and primary outcome data presented in 2023.
AACR Presentation: Monday, April 11 in the Phase II Clinical Trials 1 between 9:00 a.m. and 12:30 p.m. CST.
Neurodegenerative Disease:

Phase 1/2a Alzheimer’s Disease Trial: Topline data are expected in 2023.
ActivMAb Updates:

As previously announced, the Company has entered into several collaborations with pharmaceutical and biotechnology companies employing the unique capabilities of our ActivMAb antibody discovery platform to address difficult to drug multi-pass membrane receptors including G-protein Coupled Receptors (GPCRs) and ion channels known to be strongly associated with diseases.

Financial Results for the Twelve Months Ended December 31, 2021:

Cash and Cash Equivalents and Marketable Securities. Cash and cash equivalents and marketable securities on December 31, 2021 were $8.6 million, as compared to $10.6 million as of December 31, 2020. In January, 2022, the Company sold 3,115,197 shares of its common stock at a weighted average price of $1.16 through the Open Market Sale Agreement, and 8,747,744 shares of the Company’s common stock at a price of $1.11 through a private placement sale.

Research and Development Expenses. Research and development expenses for the year ended December 31, 2021 were $17.2 million as compared to $21.5 million for the comparable period in 2020.

Research and Development expenses are lower in 2021 compared to 2020 primarily attributed to a smaller number of patients enrolled in clinical trials, especially the CLASSICAL-Lung and SIGNAL studies.

General and Administrative Expenses. General and administrative expenses for the year ended December 2021 were $6.2 million as compared to $7.4 million for the comparable period in 2020.

The difference in general and administrative expenses is primarily attributable to planned cost reductions, as part of cost control measures.

Comprehensive loss/Net loss per share. The Comprehensive Loss and Net loss per share for the year ended December 31, 2021 was $22.4 million and $0.78 compared to $28.9 million and $1.54 for the comparable period in 2020.

Financial results are included below. For further details on Vaccinex’s financials, refer to its Form 10-K filed March 31, 2022 with the Securities and Exchange Commission.

About Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody that inhibits SEMA4D, which regulates chronic inflammation in the tumor microenvironment. Preclinical and clinical data show that pepinemab promotes infiltration of activated immune cells while reducing immune suppression in tumors and repair or prevention of neurological damage in neuroinflammatory and neurodegenerative diseases.

Results of a Phase 1b/2 study were presented at ASCO (Free ASCO Whitepaper) 2020 and were highlighted in the July 2021 publication of Clinical Cancer Research. The Company believes that results of this Phase 1b/2 CLASSICAL-Lung trial supports increased benefit of combination immunotherapy relative to historical results for checkpoint inhibitor alone as a treatment for immunotherapy naïve patients with PD-L1 low non-small cell lung cancer (NSCLC). In addition, the Company believes that its recently completed phase 2 study of single agent pepinemab in Huntington’s disease indicated both cognitive benefit and a reduction in brain atrophy and reversal of disease-associated loss of brain metabolic activity. Topline data for the SIGNAL Phase 2 trial was reported in September 2020 and more detailed analysis of the data was presented at medical conferences in April and September of 2021.

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of SIGNAL trials for HD and AD, as well as the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: clinicaltrials.gov link.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.